Clinical significance of the CD98hc-CD147 complex in ovarian cancer: a bioinformatics analysis

References

• Börner, C., et al., 2018. Pain mechanisms in peritoneal diseases might be partially regulated by estrogen. Reproductive Sciences, 25 (3), 424–434.
   PubMed Web of Science ®Google Scholar
• Cano-Crespo, S., et al., 2019. CD98hc (SLC3A2) sustains amino acid and nucleotide availability for cell cycle progression. Scientific Reports, 9 (1), 14065.
   PubMedGoogle Scholar
• Cantor, J.M., 2014. CD98 is a potential target for ablating B cell clonal expansion and autoantibody in multiple sclerosis. Journal of Neuroimmunology, 274 (1-2), 230–233.
   PubMed Web of Science ®Google Scholar
• Chu, D., et al., 2014. CD147 expression in human gastric cancer is associated with tumor recurrence and prognosis. PLoS One, 9 (6), e101027.
   PubMed Web of Science ®Google Scholar
• Cui, Y., et al., 2018. ZEB1 promotes chemoresistance to cisplatin in ovarian cancer cells by suppressing SLC3A2. Chemotherapy, 63 (5), 262–271.
   PubMed Web of Science ®Google Scholar
• Cybula, M. and Bieniasz, M., 2022. Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates. Oncotarget, 13, 553–575.
   PubMedGoogle Scholar
• de la Cruz Concepción, B., et al., 2022. EMMPRIN is an emerging protein capable of regulating cancer hallmarks. European Review for Medical and Pharmacological Sciences, 26 (18), 6700–6724.
   PubMed Web of Science ®Google Scholar
• El Ansari, R., et al., 2018. The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes. British Journal of Cancer, 118 (8), 1115–1122.
   PubMed Web of Science ®Google Scholar
• Fagotti, A., et al., 2020. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). International Journal of Gynecological Cancer, 30 (11), 1657–1664.
   PubMed Web of Science ®Google Scholar
• Gao, L., et al., 2021. Interaction of CD147 and human epididymis protein 4 promotes invasion and metastasis of ovarian cancer. Journal of Cancer, 12 (24), 7422–7435.
   PubMed Web of Science ®Google Scholar
• Geng, J., et al., 2021. CD98-induced CD147 signaling stabilizes the Foxp3 protein to maintain tissue homeostasis. Cellular & Molecular Immunology, 18 (12), 2618–2631.
   PubMed Web of Science ®Google Scholar
• Hu, J., et al., 2010. Involvement of HAb18G/CD147 in T cell activation and immunological synapse formation. Journal of Cellular and Molecular Medicine, 14 (8), 2132–2143.
   PubMed Web of Science ®Google Scholar
• Hu, Z., et al., 2016. The fucosylated CD147 enhances the autophagy in epithelial ovarian cancer cells. Oncotarget, 7 (50), 82921–82932.
   PubMedGoogle Scholar
• Huang, Y., et al., 2005. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Research, 65 (16), 7446–7454.
   PubMed Web of Science ®Google Scholar
• Ip, H. and Sethi, T., 2016. CD98 signals controlling tumorigenesis. The International Journal of Biochemistry & Cell Biology, 81 (Pt A), 148–150.
   PubMedGoogle Scholar
• Kaira, K., et al., 2014. CD98 is a promising prognostic biomarker in biliary tract cancer. Hepatobiliary & Pancreatic Diseases International : HBPD INT, 13 (6), 654–657.
   PubMed Web of Science ®Google Scholar
• Köseer, A.S., et al., 2022. Validation of CD98hc as a therapeutic target for a combination of radiation and immunotherapies in head and neck squamous cell carcinoma. Cancers, 14 (7), 1677.
   PubMed Web of Science ®Google Scholar
• Králíčková, M., et al., 2020. Endometriosis and risk of ovarian cancer: what do we know? Archives of Gynecology and Obstetrics, 301 (1), 1–10.
   PubMed Web of Science ®Google Scholar
• Laganà, A.S., et al., 2015. Cytogenetic analysis of epithelial ovarian cancer’s stem cells: an overview on new diagnostic and therapeutic perspectives. European Journal of Gynaecological Oncology, 36 (5), 495–505.
   PubMed Web of Science ®Google Scholar
• Li, S., et al., 2022. Clinical characteristics and survival outcomes in patients with ovarian strumal carcinoid. BMC Cancer, 22 (1), 1090.
   PubMed Web of Science ®Google Scholar
• Liu, B., et al., 2017. Overexpression of EMMPRIN is associated with lymph node metastasis and advanced stage of non-small cell lung cancer: a retrospective study. BMC Pulmonary Medicine, 17 (1), 214.
   PubMedGoogle Scholar
• Liu, Z., et al., 2012. Deletion of CD98 heavy chain in T cells results in cardiac allograft acceptance by increasing regulatory T cells. Transplantation, 93 (11), 1116–1124.
   PubMed Web of Science ®Google Scholar
• Marchetti, C., et al., 2012. Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opinion on Investigational Drugs, 21 (10), 1575–1584.
   PubMed Web of Science ®Google Scholar
• Musella, A., et al., 2017. Bevacizumab in ovarian cancer: state of the art and unanswered questions. Chemotherapy, 62 (2), 111–120.
   PubMed Web of Science ®Google Scholar
• Satoh, T., et al., 2017. Prognostic significance of the expression of CD98 (4F2hc) in gastric cancer. Anticancer Research, 37 (2), 631–636.
   PubMed Web of Science ®Google Scholar
• Scalise, M., et al., 2020. Membrane transporters for amino acids as players of cancer metabolic rewiring. Cells, 9 (9), 2028.
   PubMed Web of Science ®Google Scholar
• Shang, Y.K., et al., 2018. System analysis of the regulation of the immune response by CD147 and FOXC1 in cancer cell lines. Oncotarget, 9 (16), 12918–12931.
   PubMedGoogle Scholar
• Siegel, R.L., et al., 2021. Cancer statistics, 2021. CA: A Cancer Journal for Clinicians, 71 (1), 7–33.
   PubMed Web of Science ®Google Scholar
• Sung, H., et al., 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians, 71 (3), 209–249.
   PubMed Web of Science ®Google Scholar
• Upadhyay, A., et al., 2022. Early-Stage epithelial ovarian cancer: predictors of survival. Gynecologic Oncology Reports, 44, 101083.
   PubMed Web of Science ®Google Scholar
• Wang, C., et al., 2018. CD147 induces epithelial-to-mesenchymal transition by disassembling cellular apoptosis susceptibility protein/E-cadherin/β-catenin complex in human endometriosis. The American Journal of Pathology, 188 (7), 1597–1607.
   PubMed Web of Science ®Google Scholar
• Xu, D. and Hemler, M.E., 2005. Metabolic activation-related CD147-CD98 complex. Molecular & Cellular Proteomics : MCP, 4 (8), 1061–1071.
   PubMed Web of Science ®Google Scholar
• Yang, H. and Chen, B., 2013. CD147 in ovarian and other cancers. International Journal of Gynecological Cancer, 23 (1), 2–8.
   PubMed Web of Science ®Google Scholar
• Yang, H., et al., 2007. Bridge linkage role played by CD98hc of anti-tumor drug resistance and cancer metastasis on cisplatin-resistant ovarian cancer cells. Cancer Biology & Therapy, 6 (6), 942–947.
   PubMed Web of Science ®Google Scholar
• Zhang, W., et al., 2022. Expression of CD147 after neoadjuvant chemotherapy and its relationship with prognosis in patients with triple negative breast cancer. American Journal of Translational Research, 14 (5), 2952–2961.
   PubMed Web of Science ®Google Scholar